Differences in lung bioavailability between different propellants for fluticasone propionate

The lung bioavailability (as adrenal suppression) of fluticasone propionate was about two-fold greater with chlorofluorocarbons than hydrofluoroalkane as propellant. Direct switching between formulations on a μg equivalent may therefore be inadvisable.

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 1999-10, Vol.354 (9187), p.1357-1358
Main Authors: Wilson, Andrew M, Sims, Erika J, Orr, Linda C, Lipworth, Brian J
Format: Article
Language:English
Subjects:
Adult
Aerosol Propellants
Aerosols
Androstadienes - pharmacokinetics
Anti-Asthmatic Agents - pharmacokinetics
Asthma
Bioavailability
Biological and medical sciences
Biological Availability
Chlorofluorocarbons
Dose-Response Relationship, Drug
Fluticasone
Humans
Hydrocarbons, Fluorinated
Hydrocortisone - urine
Lung - drug effects
Lung - metabolism
Medical sciences
Pharmaceutical industry
Pharmacology. Drug treatments
Respiratory system
Single-Blind Method
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The lung bioavailability (as adrenal suppression) of fluticasone propionate was about two-fold greater with chlorofluorocarbons than hydrofluoroalkane as propellant. Direct switching between formulations on a μg equivalent may therefore be inadvisable.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(99)03581-3